Hims & Hers review: the household name, with the longest rap sheet
Verdict
Post–Novo Nordisk deal (March 2026), Hims & Hers sells branded medications — Wegovy, Ozempic, Zepbound — at some of the sharpest platform prices going (Ozempic from $149/month is notable), on a $149/month membership. But no provider in our comparison carries more open legal baggage: an active FTC lawsuit (July 2026) alleging deceptive subscription/cancellation practices and sharing sensitive patient data with ad platforms, a 2025 FDA warning letter from its compounded era, securities litigation, and a consumer class action. The product offering is now clean; the company's practices are what regulators are litigating. Weigh that before handing over a card number and a health questionnaire.
Branded, FDA-approved meds Aggressive med pricing Active FTC lawsuit Data-sharing allegations
What it actually costs
| Item | Price | Notes |
|---|---|---|
| Membership | $149/mo | $39 first month |
| Ozempic® | $149–299/mo | By dose tier |
| Wegovy® pill | $249/mo | |
| Wegovy® pen | $299/mo | |
| Zepbound® | $399/mo | |
| Typical all-in | ~$298–548/mo | Membership + medication; higher tiers exist for some combinations |
Note: Hims' drug-pricing page restricts automated access, so we verified these figures across its published materials and multiple third-party trackers on the same day; treat the checkout page as final. As with Ro, every medication here is also available manufacturer-direct without a membership — that comparison should be your first stop.
The legal record, itemized
- FTC + State of Utah + LA County lawsuit, July 2026 — alleges deceptive subscription and cancellation practices and sharing sensitive patient data with advertising platforms. Active.
- FDA warning letter, September 2025 — compounded-GLP-1 marketing claims, from the pre-settlement era.
- Novo Nordisk patent/false-marketing suit, February 2026 — resolved March 9, 2026 in a settlement that converted Hims into a Novo distribution partner and ended compounded semaglutide for new patients (a narrow "clinical necessity" carve-out remains).
- Securities class action (2025, ongoing) and related investigations — over statements made about compounded-semaglutide safety.
- Consumer class action — over past "same as Ozempic/Wegovy" advertising.
None of this is a verdict, and millions of people use the platform without incident. But the FTC complaint goes to the two things that matter most in a subscription-medicine relationship — whether you can leave easily, and what happens to your health data — so we'd read it (it's public) before enrolling, and we'd use the minimum necessary disclosures in the intake.
Where Hims wins
- Lowest branded Ozempic platform price we found ($149/mo entry tier)
- Full branded lineup post-Novo partnership
- Slick app, fast async intake, all 50 states
- Enormous scale — this is not a company that disappears mid-treatment
Where it doesn't
- Active FTC suit on cancellation practices and health-data sharing
- Longest litigation/warning-letter history in our comparison
- Membership stacks on medication cost, like Ro
- $39 → $149 membership jump after month one
Who should pick Hims & Hers
Price-focused branded-med shoppers who want that $149 Ozempic tier or Novo-partnership pricing and are unbothered by the open litigation — ideally cancel-tested (set a calendar reminder, verify the cancel flow in week one). If the legal record bothers you, Ro sells the same class of products with a clean sheet, and manufacturer-direct programs skip the membership entirely.
Back to full comparison Check Hims' current pricing